Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Bray, Kevin ^a   Mathew, Robin ^a,b   Lau, Alexandria ^c   Kamphorst, Jurre J ^e   Fan, Jing ^e   Chen, Jim ^a   Chen, Hsin Yi ^a   Ghavami, Anahita ^a   Stein, Mark ^a,b   DiPaola, Robert S ^a,b   Zhang, Donna ^c   Rabinowitz, Joshua D ^e   White, Eileen ^a,b,d  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d RUTGERS UNIVERSITY   (United States)

^e PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE; REACTIVE OXYGEN METABOLITE; TEMSIROLIMUS; TRANSCRIPTION FACTOR NRF2;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CANCER RESISTANCE; CELL DEATH; CELL FUNCTION; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME SYNTHESIS; GENE SEQUENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE PHOSPHORYLATION; PROTEIN FUNCTION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; AUTOPHAGY; BASAL METABOLISM; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; CHLOROQUINE; HUMANS; MICE; MITOCHONDRIA; NECROSIS; NF-E2-RELATED FACTOR 2; OXIDATION-REDUCTION; PROTEIN KINASE INHIBITORS; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864389175     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041831     Document Type: Article

References (74)

1. Levine B, Kroemer G, (2008) Autophagy in the pathogenesis of disease. Cell 132: 27-42.
2. Tsukamoto S, Kuma A, Murakami M, Kishi C, Yamamoto A, et al. (2008) Autophagy is essential for preimplantation development of mouse embryos. Science 321: 117-120.
3. Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, et al. (2004) The role of autophagy during the early neonatal starvation period. Nature 432: 1032-1036.
4. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, et al. (2011) Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 25: 460-470.
5. Rabinowitz JD, White E, (2010) Autophagy and metabolism. Science 330: 1344-1348.
6. Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, et al. (2009) Autophagy suppresses tumorigenesis through elimination of p62. Cell 137: 1062-1075.
7. Komatsu M, Waguri S, Koike M, Sou YS, Ueno T, et al. (2007) Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 131: 1149-1163.
8. Mathew R, Karantza-Wadsworth V, White E, (2007) Role of autophagy in cancer. Nat Rev Cancer 7: 961-967.
9. Jin S, White E, (2008) Tumor suppression by autophagy through the management of metabolic stress. Autophagy 4: 563-566.
10. Mathew R, White E, (2011) Autophagy in tumorigenesis and energy metabolism: friend by day, foe by night. Curr Opin Genet Dev 21: 113-119.
11. White E, (2012) Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer.
12. Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, et al. (2007) Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev 21: 1367-1381.
13. Karantza-Wadsworth V, Patel S, Kravchuk O, Chen G, Mathew R, et al. (2007) Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev 21: 1621-1635.
14. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, et al. (2006) Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10: 51-64.
15. White E, DiPaola RS, (2009) The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 15: 5308-5316.
16. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, et al. (2011) Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 17: 654-666.
17. Guertin DA, Sabatini DM, (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9-22.
18. Jung CH, Jun CB, Ro SH, Kim YM, Otto NM, et al. (2009) ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell 20: 1992-2003.
19. Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, et al. (2009) Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell 20: 1981-1991.
20. Hara T, Takamura A, Kishi C, Iemura S, Natsume T, et al. (2008) FIP200, a ULK-interacting protein, is required for autophagosome formation in mammalian cells. J Cell Biol 181: 497-510.
21. Ganley IG, Lam du H, Wang J, Ding X, Chen S, et al. (2009) ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy. J Biol Chem 284: 12297-12305.
22. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, et al. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456.
23. Hudes GR, (2009) Targeting mTOR in renal cell carcinoma. Cancer 115: 2313-2320.
24. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, et al. (2007) Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 117: 326-336.
25. Maclean KH, Dorsey FC, Cleveland JL, Kastan MB, (2008) Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest 118: 79-88.
26. Altman B, Jacobs S, Mason E, Michalek R, Macintyre A, et al. (2011) Autophagy is essential to suppress cell stress and to allow BCR-Abl-mediated leukemogenesis. Oncogene 30: 1855-1867.
27. Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, et al. (2007) Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 110: 313-322.
28. Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, et al. (2010) Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal 3: ra81.
29. Yang S, Wang X, Contino G, Liesa M, Sahin E, et al. (2011) Pancreatic cancers require autophagy for tumor growth. Genes Dev 25: 717-729.
30. Parkhitko A, Myachina F, Morrison TA, Hindi KM, Auricchio N, et al. (2011) Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent. Proc Natl Acad Sci U S A 108: 12455-12460.
31. Yazbeck VY, Buglio D, Georgakis GV, Li Y, Iwado E, et al. (2008) Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol 36: 443-450.
32. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, et al. (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36: 585-595.
33. Lock R, Roy S, Kenific CM, Su JS, Salas E, et al. (2011) Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol Biol Cell 22: 165-178.
34. Galluzzi L, Kroemer G, (2008) Necroptosis: a specialized pathway of programmed necrosis. Cell 135: 1161-1163.
35. Davis CW, Hawkins BJ, Ramasamy S, Irrinki KM, Cameron BA, et al. (2010) Nitration of the mitochondrial complex I subunit NDUFB8 elicits RIP1- and RIP3-mediated necrosis. Free Radic Biol Med 48: 306-317.
36. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, et al. (2008) Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 4: 313-321.
37. Yuan J, Kroemer G, (2010) Alternative cell death mechanisms in development and beyond. Genes Dev 24: 2592-2602.
38. Vanlangenakker N, Vanden Berghe T, Vandenabeele P, (2012) Many stimuli pull the necrotic trigger, an overview. Cell Death Differ 19: 75-86.
39. Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, et al. (1998) Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct 23: 33-42.
40. Edinger AL, Linardic CM, Chiang GG, Thompson CB, Abraham RT, (2003) Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res 63: 8451-8460.
41. Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, et al. (2010) Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res 70: 621-631.
42. Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, et al. (2007) Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol 292: C125-136.
43. Youle RJ, Narendra DP, (2011) Mechanisms of mitophagy. Nat Rev Mol Cell Biol 12: 9-14.
44. Narendra D, Tanaka A, Suen DF, Youle RJ, (2008) Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 183: 795-803.
45. Vives-Bauza C, Zhou C, Huang Y, Cui M, de Vries RL, et al. (2010) PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A 107: 378-383.
46. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD, (2008) Dual roles of Nrf2 in cancer. Pharmacol Res 58: 262-270.
47. Sun Z, Zhang S, Chan JY, Zhang DD, (2007) Keap1 controls postinduction repression of the Nrf2-mediated antioxidant response by escorting nuclear export of Nrf2. Mol Cell Biol 27: 6334-6349.
48. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, et al. (2010) The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 12: 213-223.
49. Lau A, Wang XJ, Zhao F, Villeneuve NF, Wu T, et al. (2010) A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol Cell Biol 30: 3275-3285.
50. Salazar M, Rojo AI, Velasco D, de Sagarra RM, Cuadrado A, (2006) Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J Biol Chem 281: 14841-14851.
51. Merchan JR, Pitot HC, Qin R, Liu G, Fitch TR, et al. (2009) Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): Safety and activity in RTKI refractory RCC patients.??J Clin Oncol (Meeting Abstracts) 27: 5039.
52. Efeyan A, Sabatini DM, (2010) mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 22: 169-176.
53. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, et al. (2008) Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4: 151-175.
54. Ding WX, Ni HM, Gao W, Chen X, Kang JH, et al. (2009) Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. Mol Cancer Ther 8: 2036-2045.
55. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, et al. (2009) Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 119: 1109-1123.
56. Degtyarev M, De Maziere A, Orr C, Lin J, Lee BB, et al. (2008) Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol 183: 101-116.
57. Turcotte S, Chan DA, Sutphin PD, Hay MP, Denny WA, et al. (2008) A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell 14: 90-102.
58. Turcotte S, Sutphin PD, Giaccia AJ, (2008) Targeted therapy for the loss of von Hippel-Lindau in renal cell carcinoma: a novel molecule that induces autophagic cell death. Autophagy 4: 944-946.
59. Boya P, Gonzalez-Polo RA, Casares N, Perfettini JL, Dessen P, et al. (2005) Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 25: 1025-1040.
60. Kaiser WJ, Upton JW, Long AB, Livingston-Rosanoff D, Daley-Bauer LP, et al. (2011) RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 471: 368-372.
61. Oberst A, Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, et al. (2011) Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 471: 363-367.
62. Zhang H, Zhou X, McQuade T, Li J, Chan FK, et al. (2011) Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature 471: 373-376.
63. Cho YS, Challa S, Moquin D, Genga R, Ray TD, et al. (2009) Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 137: 1112-1123.
64. Upton JW, Kaiser WJ, Mocarski ES, (2010) Virus inhibition of RIP3-dependent necrosis. Cell Host Microbe 7: 302-313.
65. Galluzzi L, Vanden Berghe T, Vanlangenakker N, Buettner S, Eisenberg T, et al. (2011) Programmed necrosis from molecules to health and disease. Int Rev Cell Mol Biol 289: 1-35.
66. Horita H, Frankel AE, Thorburn A, (2008) Acute myeloid leukemia-targeted toxin activates both apoptotic and necroptotic death mechanisms. PLoS One 3: e3909.
67. Hu X, Han W, Li L, (2007) Targeting the weak point of cancer by induction of necroptosis. Autophagy 3: 490-492.
68. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, et al. (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68: 3421-3428.
69. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, et al. (2008) Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci U S A 105: 13568-13573.
70. Anglard P, Trahan E, Liu S, Latif F, Merino MJ, et al. (1992) Molecular and cellular characterization of human renal cell carcinoma cell lines. Cancer Res 52: 348-356.
71. Grossman HB, Wedemeyer G, Ren LQ, (1985) Human renal carcinoma: characterization of five new cell lines. J Surg Oncol 28: 237-244.
72. Nelson DA, Tan TT, Rabson AB, Anderson D, Degenhardt K, et al. (2004) Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev 18: 2095-2107.
73. Root DE, Hacohen N, Hahn WC, Lander ES, Sabatini DM, (2006) Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods 3: 715-719.
74. Munger J, Bajad SU, Coller HA, Shenk T, Rabinowitz JD, (2006) Dynamics of the cellular metabolome during human cytomegalovirus infection. PLoS Pathog 2: e132.